Stocx Research Club logo ×
Screener Research Unlisted Startup Funding IPO


New Delhi, India

Akshita is an equity research analyst working with a US Research firm and an aspiring CFA charter. With a keen interest in financial modeling and valuation, she prepares exemplary-detailed research reports.

Read More..
Contributor since: 2022







Equity Research Report: Sakar Healthcare

Sakar Healthcare Ltd is engaged in manufacturing of pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injectables and syrups. Presently, its domestic sales accounts for 31% of revenues and exports accounts for the rest of 69% of revenues. It is one of the fastest growing pharma company in India.


Company issued preference shares to FII (A Swiss based HBM Healthcare Investments; a global healthcare private equity invested Rs 14.85 crore in Sakar Healthcare through its wing Cobra India Mauritius limited). HBM Healthcare Investments through COBRA actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and other healthcare related area. It invests 17% of its total investments into Oncology (which is third largest area of its investment). HBM takes an active role and assumes entrepreneurial responsibility together with the management team.This 14.85CR was used for setting up of new manufacturing units pertaining to anti-cancer (oncology) Project. 



Anti-cancer (oncology) Project

  • Anti-cancer (oncology) is a Treatment to stop or prevent cancer. Since cancer is the second largest cause of death in the India, the Indian market is characterized by a huge demand for cancer drugs.
  • Standalone oncology unit would include-

    • FORMULATION: Technology enhanced Lab (R&D, Analytical Development & formulations & development), It started with Research laboratories on September 22, 2021

    • INJECTIONS: Liquid & lyophilised injections

    • API

    • Robust Manufacturing unit for finished formulation viz Oral Solid dosage form.

  • Total cost of this project is Rs 145.76 CR out of which 14.85 CR was raised from FII, the company has been raising debt for the same reason, In FY21 SAKAR showed borrowing of 42.59 CR (Secured by PPE & company’s car) & in Q3 FY21 it raised borrowing by 23.44 CR. (Credit rating: [ICRA]BBB(Stable))




  • Net profit of Sakar Healthcare rose 417.34% to Rs 8.95 crore in the quarter ended March 2022 as against Rs 1.73 crore during the previous quarter ended March 2021. Sales rose 68.77% to Rs 36.59 crore in the quarter ended March 2022 as against Rs 21.68 crore during the previous quarter ended March 2021.
  • For the full year,net profit rose 42.13% to Rs 15.18 crore in the year ended March 2022 as against Rs 10.68 crore during the previous year ended March 2021. Sales rose 35.35% to Rs 128.23 crore in the year ended March 2022 as against Rs 94.74 crore during the previous year ended March 2021


  • Sakar’s topline for the fiscal 2020-21 grew by 14.17% to Rs. 94.74 crores from Rs. 82.98 crores compared with the same period a year ago primarily driven by exports to Asian & African countries.
  • EBITDA increased by 11.79 % to Rs. 24.10 Cr. from Rs. 21.56 Cr.
  • Net profit increased by 11.11% to Rs. 10.69 crores from Rs. 9.62 crores.



Sakar's R&D team has been working constantly on its ongoing oncology project, Total R&D expenditure has increased from 3.36 CR to 6.97 CR. 











  • Increase High Margin ExportsSakar's exports have grown by over 2.3 times in the last three years and is expected to continue to grow at a fast clip as the driven by company's push into regulated markets. The company last year received EU GMP for its Liquid & Lyophilized injectable facility which will open up regulated markets for it. Exports contribute 80% of company's EBITDA. In addition, with commencement of Oncology plant exports will get further fillip thus positively impacting margins across the board
  • Oncology (anti-cancer) unit to drive exponential growthEntry into the fastest growing therapeutic segment with high barriers to entry will give a big fillip to company's growth for the next many years. This state of the art manufacturing facility has been designed according to the USFDA standards and will help the company to sell its Onco products into regulated markets.


  • Established track record of over 17 years in the pharmaceuticals formulation industry: The company has had established operations of more than 17 years in manufacturing pharmaceutical formulations. SHL manufactures generic formulations in 23 therapeutic categories, such as antibiotics, antihistamine, antifungal, cough preparation, and vitamins, among others.
  •  Diversified product portfolio and geographic presence: The company’s product profile is diversified, comprising liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injections and syrups. SHL’s product portfolio includes approximately 300 product registrations for various therapeutic segments, such as antibiotics, anti-cold drugs, anti-malarial, and multi-vitamins, among others


  • Risks associated with stabilisation and successful scale-up of operations for recently completed and ongoing debt-funded project for manufacturing oncology drugs: SHL has undertaken a debt-funded capital expenditure (capex) for setting up a new plant to manufacture oncology drugs. The formulation unit achieved commercial operations in October 2021 whereas the operations of API unit is expected to commence in next six months and the injectable unit is expected to commence from December 2022.
  • Profitability remains susceptible to fluctuations in raw material prices: The company’s major raw materials include APIs, such as Paracetamol, Artemether and Diclofenac; and procures it from domestic suppliers all over the country. SHL’s profitability, hence, remains susceptible to such raw material price fluctuations. The operating margin during H1 FY2022 moderated by 238bps over full year FY2021 on account of the inflationary raw material regime, wherein the ability to fully pass on such costs remain critical to protect margins.



Increase in revenue is expected in upcoming quarters from Oncology formulation & API unit, commencement of Oncology API & Injectables will start after September’22 & December’22. A significant improvement in the operating income of the company on the back of scale-up of the new plant, while maintaining healthy profitability and debt coverage indicators is expected. 




I/we have no positions in any stocks mentioned, but may initiate a position.

Business relationship disclosure:

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Stocx Research Club). I have no business relationship with any company whose stock is mentioned in this article.

Disclosure legality:

I am not a SEBI Registered individual/entity and the above research article is only for educational purpose and is never intended as trading/investment advice.


Updated : Jun, 2023

Equity Research Report: Adani Enterprises

In FY23, core operating EPS jumped almost +295% due to the lower base effect of various incubating businesses (airports, roads); the trend may continue in FY24-25 too

Author : Ashish Ghosh

Updated : Jun, 2023

Initial Coverage: Indigo Paints

The company has a strong presence in tier III and tier IV markets, where brand penetration is relatively easy, and dealers have more power to influence customers’ buying decisions and these markets allowed the company to expand its brand and presence...

Author : Akshita

Updated : Jun, 2023

Equity Research: Triveni Turbine

With an installation base of 5,000 turbines in more than 70 countries, TRIV is the second largest industrial steam turbine player globally. Triveni turbine looks strong with increasing order book along with rising export opportunity

Author : Shalom Martin

Updated : Jun, 2023

IKIO Lighting Limited

A IPO Analysis

Author : Akshay Rajawat

Updated : Jun, 2023

Godrej Consumer Products Ltd. (GCPL)

Q4FY23 and FY23 Result Analysis

Author : Aditya Sharma

Updated : Jun, 2023

SOM Distilleries & Breweries Limited: Favourable dem...

SOM Distilleries & Breweries Limited is only listed company in India having both Beer and IMFL, which complement each other and minimizes risk of seasonality while providing marketing efficiencies. The company continues to focus on enhancing brand pre...

Author : TheAsianInvestor

Updated : Jun, 2022

Equity Research Report: Sakar Healthcare

Sakar Healthcare Ltd is engaged in manufacturing of pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injectables and syrups. Presently, its domestic sales accounts for 31% of revenues and ...

Author : Akshita

Updated : Jun, 2022


Newgen Software Technologies is a global software Company and is engaged in the business of software product development including designing and delivering end-to-end software solutions covering the entire spectrum of software services from workflow au...

Author : Akshita

Updated : Jun, 2022

Nifty and Bank Nifty Tumbles Due to Weak Global Cues...

Nifty and Bank Nifty tumbles due to weak global cues lead by higher inflation data, higher crude oil prices and weakening currency.

Author : Shalom Martin

Updated : Jun, 2022

Equity Research Report: Shree Renuka Sugar

Shree Renuka Sugars is a global agribusiness and bio-energy corporation. The Company is one of the largest sugar producers in the world, the leading manufacturer of sugar in India, and one of the largest sugar refineries in the world.

Author : Akshita

Updated : Jul, 2022

Equity Research : Tata Consumer Products Limited

TCPL future ambitions remain aggressive, At 17% EPS CAGR over FY22-25e, TCPL should deliver industry-leading growth within indian FMCG.

Author : Shalom Martin

Updated : Jul, 2022

Equity Research: Birlasoft Ltd

Birlasoft, a small-cap IT company, has an upside potential of 35%. The company’s repeated demonstration of ‘walking the talk’ makes us believe that it is on track to achieve its stated target of USD1bn revenue by FY25E.

Author : Shalom Martin


  • Ruchi Bali

    26 June, 2022, 10:47 am
    Detailed report
  • Vishal

    26 June, 2022, 6:27 pm
    Really helpful information. Also the point to point description allow you to get detailed information.
  • arshdeep kaur

    26 June, 2022, 7:09 pm
    Really well put and explanatory.